Diabetes Management
Amphilimus- vs zotarolimus-eluting stents: Any preference in patients with diabetes? | Latest news for Doctors, Nurses and Pharmacists | Pharmacy - MIMS
Thu, 27 Oct 20221 min read Article
Overview
Updated results of the SUGAR* trial showed that using polymer-fre amphilimus-eluting stents (AES) was not a superior option to durable-polymer zotarolimus-eluting stents (ZES) in patients with diabetes melitus who required percutaneous coronary intervention (PCI).“At 2 years, there is insuficient evidence that AES are superior to ZES with regard to target lesion failure (TLF) in patients with diabetes undergoing PCI,” remarked study author Dr Pablo Salinas from the Hospital Clínico San Carlos and Instituto de Investigación Sanitaria del Hospital Clínico San Carlos in Madrid, Spain, at TCT 2022.Participants in this 23-centre study from Spain were 1,175 patients with diabetes melitus (95.5 percent with type 2 diabetes) who required PCI.
Key Information
They were randomized 1:1 to undergo PCI with polymer-fre AES (70–80 µm thicknes) or durable-polymer ZES (92–102 µm thicknes). Patients who were pregnant, had cardiogenic shock, life expectancy <2 years, required mechanical ventilation, or with a contraindication to dual antiplatelet therapy were excluded. At baseline, 32 percent of patients were on insulin therapy.
Fifty-one percent had multivesel disease. One-year results showed non-inferiority betwen stents for the outcome of TLF (defined as a composite of cardiac death, target vesel myocardial infarction [MI], or target vesel revascularization; 7.2 percent [AES] vs 10.9 percent [ZES]; hazard ratio [HR], 0.65, 95 percent confidence interval [CI], 0.4–0.96; pnoninferiority<0.01). [Eur Heart J 2022;43:1320-130]However, the pre-specified exploratory analysis for superiority at 1 year sugested that AES may be superior to ZES (psuperiority=0.030), noted Salinas.
Summary
The present analysis at 2 years, which was powered for superiority and included 578 and 586 patients in the AES and ZES groups, respectively, did not demonstrate superiority of AES over ZES in terms of TLF (10.4 percent vs 12.1 percent; HR, 0.84, 95 percent CI, 0.60–1.19; p=0.31). [TCT 2022, sesion: Late-Bre
Frequently Asked Questions
What is diabetes and how does it develop?
Diabetes is a metabolic condition where the body cannot properly regulate blood sugar levels. Type 1 results from insufficient insulin production, while Type 2 develops when cells become resistant to insulin. Risk factors include genetics, obesity, sedentary lifestyle, and age.
What are the main symptoms of diabetes?
Common symptoms include excessive thirst, frequent urination, unexplained weight loss, fatigue, blurred vision, and slow-healing wounds. Type 1 symptoms develop rapidly, while Type 2 symptoms may appear gradually. Many people have no symptoms initially, which is why screening is important.
How is diabetes diagnosed and monitored?
Diagnosis involves blood tests measuring fasting glucose, HbA1c levels, and glucose tolerance. Regular monitoring typically includes fasting glucose tests and HbA1c measurements every 3-6 months. Continuous glucose monitors provide real-time tracking for better diabetes management.
What lifestyle changes help manage diabetes?
Effective management includes regular physical activity (150+ minutes weekly), maintaining healthy weight, following a balanced diet with whole grains and lean proteins, managing stress, and getting adequate sleep. These changes can significantly improve blood sugar control and reduce complications.
When should someone consult a doctor about diabetes?
Consult a healthcare provider if you experience signs of diabetes, have a family history, are overweight, or are over 45. Those with existing diabetes should maintain regular check-ups every 3-6 months to monitor control and adjust treatment as needed.
️ Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions.